OncLive® and the Ruesch Center for the Cure of Gastrointestinal Cancers announce recipients of the 2024 Luminary Awards in GI Cancers CRANBURY, N.J., Oct. 09, 2024 (GLOBE NEWSWIRE) -- OncLive, the nation’s leading multimedia resource for oncology professionals, and the Ruesch Center for the Cure of Gastrointestinal (GI) Cancers at...

OncLive® and the Ruesch Center for the Cure of Gastrointestinal Cancers Name Winners of the 2023 Luminary Awards in GI Cancers CRANBURY, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- OncLive, the nation’s leading multimedia resource for oncology professionals, and The Ruesch Center for the Cure of Gastrointestinal (GI) Cancers,...

OncLive and the Ruesch Center for the Cure of Gastrointestinal Cancers Name Winners of the 2022 Luminary Awards in Gastrointestinal Cancers CRANBURY, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- OncLive®, the nation’s leading multimedia resource for oncology professionals, and The Ruesch Center for the Cure of Gastrointestinal (GI) Cancers,...

Rhizen Pharmaceuticals S.A. announces poster presentation of RP4010, a calcium release-activated calcium (CRAC) channel inhibitor in preclinical models of Gastrointestinal (GI) Cancers at the 2019 AACR Annual Meeting La Chaux-de-Fonds, Switzerland, March 26, 2019 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces poster presentation of RP4010, a novel first-in-class CRAC channel inhibitor in preclinical...